At-Home Genetics Test May Help Detect Possible Psychedelic Therapy Risks

Psychedelics are making a comeback in Western society, having started the journey to mainstream a few years ago. This renaissance has brought with it a lot of new discoveries, many of which are useful for the mental health field.

As mental health disorders increase at a rather alarming rate, the research on various psychedelics as potential alternative treatments has been welcomed by many, especially those in the psychedelic field and those who would like to indulge in psychedelics as well as users of these substances.

However, as with any other drug, psychedelics carry some risk, and with more jurisdictions beginning to loosen their enforcement on the possession and use of these drugs, the need for ways to guarantee the responsible and safe use of these substances grows.

Entheon Biomedical, a psychedelics biotech company, may offer an answer, having recently launched an at-home genetics kit earlier last month. The kit, which is delivered through the mail, can be utilized as a prescreening platform by individuals who would like to indulge in psychedelic experiences. The test is only the first among various solutions that have been suggested to help decrease possible harms that may arise from the uninformed or unregulated use of psychedelic substances.

Dr. Albert Garcia-Romeu, a researcher from Johns Hopkins University who has studied the effects of psychedelics in people, stated that most individuals who consume psychedelics are on the whole, physiologically safe. However, some risks to an individual’s body still exist, with a majority of those risks linked to cardiovascular ailments given that psychedelic substances cause an individual’s blood pressure and heart rate to increase.

Clinical studies conducted at Johns Hopkins that entail administering high doses of psychedelic substances to patients typically follow risk prevention protocols, which include performing a physical examination and an EKG to evaluate a patient’s cardiovascular function, drawing blood for further testing and taking down the patient’s detailed medical history.

The at-home genetic test kit, which bypasses this, was developed by HaluGen Life Sciences Inc. and Lobo Genetics Inc. The kit, which comprises of a cheek swab that is sent back to the company for analysis, examines risk factors based on an individual’s family history and lifestyle.

The consumers, who are also required to fill out surveys, are sent their results in a matter of days; those results highlight the mental health and specific metabolism risks found by the analysis performed. With regard to mental health, Entheon Biomedical analyzes an individual’s genetic predisposition to bipolar disorder, schizophrenia and other disorders.

Apart from highlighting whether individuals should consume lower doses at the start of their treatments given their susceptibility to hallucinogenic effects, kit results may be used as a risk measuring tool for individuals looking to commence their psychedelics-assisted therapy journey.

The psychedelics industry is currently looking more like the pharmaceutical industry rather than taking the trajectory that the cannabis sector took during its ascendance. This can be seen when you consider that companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are following the route of developing pharmaceutical formulations, which may make it easier for the medical community to accept these products since they will have been subjected to a rigorous clinical trial process.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050